Table 1.
Efficacy, cardiotoxicity and early death rate of CAG in AML
| Study (ref) | Year |
No. Patients * |
Median age (range) | Aclarubicin dosage | AML No. | AML CR No. | AML CR % | OS (m) (range) | CT No. | ED No. |
| Yamada [14] | 1995 | 18 | 44 (18-74) | 10-14 mg/m2 × 4d | 18 | 15 | 83 | 17 (2-28) | 0 | 0 |
| Saito [35] | 1995 | 18 | NR(18-74) | 10 or 14 mg/m2 × 4d | 18 | 15 | 83 | 15 (1-35) | 1 | 0 |
| Saito [36] | 1996 | 28 | NR(18-74) | 10 or 14 mg/m2 × 4d | 28 | 24 | 86 | 17 (1-47) | 0 | 0 |
| Tabata [37] | 1998 | 76 | NR(60-83) | 14 mg/m2 × 4d | 8 | 5 | 63 | NA | NA | NA |
| Saito [38] | 2000 | 69 | 51 (15-82) | 10 or 14 mg/m2 × 4d | 51 | 31 | 62 | NA | 0 | 0 |
| Hirayama [39] | 2003 | 18 | NR(65-80) | 14 mg/m2 × 4d | 9 | 6 | 67 | 9 (1-43) | 0 | 1 |
| Li [26] | 2005 | 112 | 47 (15-81) | 14 mg/m2 × 4d or 8 mg/m2 × 8d | 99 | 44 | 44 | NA | 0 | 1 |
| Kong [40] | 2005 | 20 | NR(18-80) | 10-14 mg/m2 × 4d | 20 | 11 | 55 | NA | 0 | 0 |
| Yang [41] | 2005 | 16 | NR(60-82) | 6 mg/m2 × 8d | 16 | 9 | 56 | NA | 0 | 1 |
| Huang [25] | 2005 | 30 | NR(15-67) | 5-7 mg/m2 × 8d | 30 | 22 | 73 | NA | 0 | 1 |
| Qian [19] | 2005 | 21 | NR(15-81) | 10 mg/d × 8d | 21 | 14 | 67 | NA | 0 | 2 |
| Xie [42] | 2006 | 25 | NR(55-78) | 10 mg/m2 × 4d | 25 | 12 | 48 | NA | 0 | 3 |
| Liu [27] | 2006 | 13 | NR(18-77) | 10-14 mg/m2 × 4d | 13 | 5 | 39 | NA | 0 | 0 |
| Wang [43] | 2006 | 11 | NR(25-72) | 10 mg/m2 × 8d | 11 | 4 | 36 | NA | 0 | 0 |
| Wu [44] | 2007 | 15 | NR(60-84) | 7 mg/m2 × 8d | 15 | 8 | 53 | NA | 1 | 1 |
| Qian [20] | 2007 | 50 | 65 (60-81) | 10 mg/d × 8d | 50 | 29 | 58 | 14 (1-60) | 0 | 4 |
| Su [29] | 2007 | 16 | NR | 20 mg/d × 4d | 16 | 9 | 56 | NA | 0 | 0 |
| Guo [45] | 2007 | 8 | NR(18-56) | 5-7 mg/m2×5d | 8 | 4 | 50 | NA | 0 | 0 |
| Chen [46] | 2008 | 75 | NR(60-85) | 10 mg/d × 8d | 34 | 23 | 68 | NA | 0 | 0 |
| Sang [47] | 2008 | 45 | NR(60-73) | 7 mg/m2 × 8d | 23 | 9 | 39 | NA | 0 | 1 |
| Bian [48] | 2008 | 46 | NR(18-72) | 10-14 mg/m2 × 4d | 26 | 20 | 77 | NA | 0 | 0 |
| Chai [49] | 2009 | 17 | NR | 15 mg/m2×7d | 17 | 8 | 47 | NA | 0 | 0 |
| Zhu [50] | 2009 | 50 | NR(15-69) | 10 mg/d × 8d | 30 | 14 | 47 | NA | 0 | 1 |
| Ni [51] | 2009 | 70 | NR(22-85) | 14 mg/m2 × 4d | 61 | 34 | 56 | 28 (1-89) | 0 | 3 |
| Feng [52] | 2010 | 32 | NR(60-74) | 5-7 mg/m2 × 8d | 16 | 9 | 56 | NA | 0 | 0 |
| Ma [28] | 2010 | 31 | NR(19-71) | 14 mg/m2 × 4d | 26 | 14 | 54 | NA | 0 | 0 |
| Li [53] | 2010 | 38 | NR(19-61) | 5-7 mg/m2 × 8d | 18 | 14 | 78 | NA | 0 | 0 |
| Liang [54] | 2010 | 54 | NR(17-82) | 5-7 mg/m2 × 8d | 39 | 21 | 54 | NA | 1 | 7 |
| Suzushima [55] | 2010 | 68 | 76 (60-88) | 14 mg/m2 × 4d | 68 | 33 | 49 | 9 (0-56) | NA | 15 |
Abbreviations: AML: acute myeloid leukemia; Ref: references; NA: not available; NR: not reported; *: total number of AML and MDS patients; m: month; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.